13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00645749
(ClinicalTrials.gov)		July 200825/3/2008Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple SclerosisHelminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisBiological: Helminth ovaUniversity of Wisconsin, MadisonNational Multiple Sclerosis SocietyCompleted18 Years50 YearsAll17Phase 1United States